The durability and deepening of response off treatment in both alopecia areata and atopic dermatitis are clinically meaningful differentiators versus JAK inhibitors. Initiation of Phase 3 ZENITH AA in early 2027 and the third Phase 3 AD study are key catalysts. Monitor for enrollment updates and potential partnership interest given the broad Treg mechanism.
Price Chart
Executive Summary
Nektar Therapeutics presented new Phase 2b data for rezpegaldesleukin at EADV 2026, showing durable and deepening responses in alopecia areata and atopic dermatitis. In alopecia areata, 63% of patients maintained SALT Score ≤20 at 6 months off treatment, and SALT Score ≤10 deepened from 7% at Week 52 to 19% at 6 months off treatment. A third Phase 3 study in atopic dermatitis (ZENITH AD) has been initiated, and the Phase 3 ZENITH AA study in alopecia areata is planned for early 2027. The data support a differentiated Treg mechanism with potential for durable disease control.
Key Facts
- In alopecia areata, 63% (5/8) of patients maintained SALT Score ≤20 at 6 months off treatment after 52 weeks of REZPEG dosing.
- SALT Score ≤10 deepened from 7% at Week 52 to 19% at 6 months off treatment in alopecia areata.
- In atopic dermatitis, Q4W maintenance dosing increased EASI-100 response from 4% to 22% and Q12W from 9% to 18% among all re-randomized patients from Week 16 to Week 52.
- Phase 3 ZENITH AA study in 850 patients with severe-to-very-severe alopecia areata to initiate in early 2027.
- Third Phase 3 study in the global ZENITH AD program initiated for treatment-experienced atopic dermatitis patients.
- Safety profile through 52 weeks was favorable and consistent with prior studies; discontinuation rate due to AEs was 1.4% for all REZPEG-exposed patients.
- FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis (Feb 2025) and alopecia areata (July 2025).
Financial Impact
No financial data provided in filing; clinical-stage biotech with no approved products or reported revenue from product sales.
Risk Factors
- Phase 3 trials may fail to replicate Phase 2b efficacy and safety findings.
- Competition from approved JAK inhibitors and other biologics in development.
- Clinical-stage company with no approved products; requires additional capital to fund Phase 3 programs.
- Regulatory approval timelines and approval decisions are uncertain despite Fast Track designations.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-105453 |
| Document: ea030730601ex99-1.htm | 0001213900-26-105453 |
| Document: ea0307306-8k_nektar.htm | 0001213900-26-105453 |
| Document: 0001213900-26-105453-index-headers.html | 0001213900-26-105453 |
| Document: 0001213900-26-105453-index.html | 0001213900-26-105453 |
| Document: 0001213900-26-105453.txt | 0001213900-26-105453 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $46.99 $43.58 | ▼ −7.26% | ▼ −8.00% | $37.98 (−19.17%) |
Sep 28, 2026 29d ago | SC 13G/A | $60.40 $59.24 | ▼ −1.92% | ▼ −1.74% | $37.98 (−37.12%) |
Sep 25, 2026 4w ago | 8-K | $57.06 $60.40 | ▲ +5.85% | ▲ +6.60% | $37.98 (−33.44%) |
Aug 13, 2026 10w ago | Press Release | $73.02 $72.67 | ▼ −0.48% | ▼ −0.01% | $37.98 (−47.99%) |
Aug 9, 2026 11w ago | Institutional Cluster | $74.86 $75.50 | ▲ +0.85% | ▲ +1.17% | $37.98 (−49.27%) |
Aug 7, 2026 11w ago | Court Ruling | $74.86 $75.50 | ▲ +0.85% | ▲ +1.17% | $37.98 (−49.27%) |
Jul 28, 2026 12w ago | Press Release | $70.68 $71.45 | ▲ +1.09% | ▼ −0.59% | $37.98 (−46.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $59.21 $59.38 | ▲ +0.29% | ▼ −0.25% | $37.98 (−35.86%) |
Jun 11, 2026 19w ago | Institutional Cluster | $59.21 $59.38 | ▲ +0.29% | ▼ −0.25% | $37.98 (−35.86%) |
May 21, 2026 22w ago | Insider Cluster | $66.61 $65.56 | ▲ +1.58% | ▲ +2.16% | $37.98 (+42.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers